Aadi Bioscience, Inc

96 articles about Aadi Bioscience, Inc

• Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting

  4/9/2024

  Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance.

• Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)

  3/17/2024

  Aadi Bioscience, Inc. announced patients in the AMPECT trial whose malignant perivascular epithelioid cell tumor had gynecologic origins experienced efficacy and safety consistent with the overall study population.

• Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update

  3/13/2024

  Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and highlighted recent corporate progress.

• Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update

  3/6/2024

  Aadi Bioscience, Inc. today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024.

• Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

  3/5/2024

  Aadi Bioscience, Inc. announced poster presentations at the 2024 American Association for Cancer Research, taking place April 5-10, 2024, in San Diego, CA.

• Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa

  3/1/2024

  Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-driven cancers, announced today that long-term efficacy and safety results from its completed Phase 2 registrational AMPECT study of nab-sirolimus in malignant PEComa were published in the Journal of Clinical Oncology (JCO).

• Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference

  2/26/2024

  Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, announced today its presentation at the TD Cowen 44th Annual Healthcare Conference, taking place March 4-6, 2024, in Boston.

• Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

  1/26/2024

  Aadi Bioscience, Inc. (NASDAQ: AADI) today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27, 2024, in San Francisco, CA.

• Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

  1/19/2024

  Aadi Bioscience, Inc. announced poster presentations at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, taking place January 18-20, 2024, in San Francisco, CA.

• Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

  12/14/2023

  Aadi Bioscience, Inc. (NASDAQ: AADI) today reported results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial evaluating nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations. 

• Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update

  11/8/2023

  Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced financial results for the quarter ended September 30, 2023, and highlighted recent corporate progress.

• Aadi Bioscience to Participate in Jefferies London Healthcare Conference 2023

  11/6/2023

  Aadi Bioscience, Inc., a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced participation in the Jefferies London Healthcare Conference, taking place November 14-16, 2023, in London.

• Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update

  11/1/2023

  Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023 at 8:30 am ET (5:30 am PT) to report third quarter 2023 financial results and provide an operational update.

• Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting

  10/19/2023

  Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced e-poster presentations at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting, taking place November 5-7, 2023, in Seoul, Korea.

• Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium

  10/5/2023

  Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that two posters will be presented at the upcoming North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, taking place October 4-6, 2023, in Montreal, Canada. 

• Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) - October 03, 2023

  10/3/2023

  Aadi Bioscience, Inc. announced that an equity award has been granted to its new President and Chief Executive Officer, Dave Lennon, Ph.D., on October 2, 2023, the first date of his employment, in accordance with the Aadi Bioscience, Inc. 2023 Inducement Plan.

• Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer

  10/2/2023

  Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies with mTOR pathway alterations, today announced the appointment of Dave Lennon, Ph.D. as President and Chief Executive Officer. 

• Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  9/20/2023

  Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that four abstracts have been selected for presentation at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston, MA. 

• Aadi Bioscience to Participate at Upcoming Investor Conferences - September 5, 2023

  9/5/2023

  Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with mTOR pathway alterations, announced today participation at the following investor events.

• Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update

  8/9/2023

  Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2023.